Top

Supportive Care in Cancer

Published in:

01-06-2019 | Original Article

The efficacy of oral piroxicam fast-dissolving tablets versus sublingual fentanyl in incident breakthrough pain due to bone metastases: a double-blinded randomized study

Authors: Ayman Abdalmaksoud Yousef, Ashraf Elsayed Alzeftawy

Published in: Supportive Care in Cancer | Issue 6/2019

Abstract

Purpose

Breakthrough pain (BTP) is a transient exacerbation of pain occurring in a patient with chronic, persistent pain. The most common type is incident pain that is mostly related to bone metastases. The oral mucosa is an attractive route for drug delivery. Sublingual fentanyl preparations are a very attractive agent in controlling attacks of BTP due to its rapid absorption through the oral mucosa. Non-steroidal anti-inflammatory drugs (NSAIDs) play a key role as a first step in treatment of cancer pain; piroxicam sublingual formulations could be a useful alternative in controlling incident pain. Our study hypothesis is to evaluate the efficacy of sublingual fentanyl versus oral piroxicam fast-dissolving tablets in patients with incident pain and its impact on functional status.

Patients and methods

A cohort of 100 adults of both genders suffering from bone metastases. Patients were assigned to receive either sublingual fentanyl tablet (group 1) or oral piroxicam fast-dissolving tablets (group 2). The pain intensity reduction on a 0–10 visual analog scale (VAS), frequency of BTP attacks, and onset of pain relief. Secondary end points included the functional interference items of the Brief Pain Inventory (BPI).

Results

There is no significant difference between the two groups regarding the patients’ demographics. Significant decline of the VAS in each group in comparison to the pretreatment values (p = 0.001). Non-significant changes of the VAS, duration of pain attacks, and number of rescue doses in comparing both groups were measured. There was significant reduction in group 2 BPI regarding the relation with others, sleep pattern and enjoyment of life parameters at 2 and 4 weeks (p = 0.001).

Conclusion

Our study demonstrated that oral piroxicam fast-dissolving tablet is an analgesic alternative to sublingual fentanyl in patients with bone metastasis to control incidental BTP attacks with more favorable cost-benefit values.

Margarit C, Juliá J, López R, Anton A, Escobar Y, Casas A, Cruz JJ, Galvez R, Mañas A, Zaragozá F (2012) Breakthrough cancer pain– still a challenge. J Pain Res 5:559–566CrossRefPubMedPubMedCentral

Mishra S, Bhatnagar S, Chaudhary P, Pratap S, Rana S (2009) Breakthrough cancer pain: review of prevalence, characteristics and management. Indian Journal of Palliative Care 15(1):14–18CrossRefPubMedPubMedCentral

Patel VF, Liu F, Brown MB (2011) Advances in oral transmucosal drug delivery. J Control Release 153:106–116CrossRefPubMed

Lennernäs B, Frank-Lissbrant I, Lennernäs H, Kälkner KM, Derrick R, Howell J (2010) Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain; results from a randomized phase II study. Palliat Med 24:286–293CrossRefPubMed

Omoti AE, Omoti CE (2007) Pharmacological strategies for the management of cancer pain in developing countries. Pharm Pract 5(3):99–104

Kuo KL, Saokaew S, Stenehjem DD (2013) The pharmacoeconomics of breakthrough cancer pain. J Pain Palliat Care Pharmacother 27(2):167–175CrossRefPubMed

Mercadante S, Radbruch L, Caraceni A, Cherny N, Kaasa S, Nauck F, Ripamonti C, De Conno F (2002) Episodic (breakthrough) pain consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94:832–839CrossRefPubMed

Mercadante S, Villari P, Ferrera P, Casuccio A (2004b) Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manag 28:505–510CrossRef

San K, Carla MB, Sheri LD, Jeff S, Tito RM, Charles SC (2004) Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 20(5):309–318CrossRef

10.

Zhang H, Zhang J, Streisand JB (2002) Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet 41:661–680CrossRef

11.

Payne R (1997) Mechanisms and management of bone pain. Cancer Supplement 80(8):1608–1613CrossRef

12.

Yalcin S, Altundag K, Asil M, Tekuzman G (1998) Sublingual piroxicam for cancer pain. Med Oncol 15:137–139CrossRefPubMed

13.

Gَmez-Batiste X, Madrid F, Moreno F, Gracia A, Trelis J, Nabal M et al (2002) Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manag 24:45–52CrossRef

14.

Davies AN, Vriens J, Kennett A, McTaggart M (2008) An observational study of oncology patients’ utilisation of breakthrough pain medication. J Pain Symptom Manag 35(4):406–411CrossRef

15.

Janecki M, Janecka J (2011) Breakthrough pain in patients with chronic cancer pain followed by palliative care and pain clinic physicians — an observational study. Palliat Med 10(1):29–34

16.

Rauck RL, Tark M, Reyes E, Hayes TG, Bartkowiak AJ, Hassman D, Nalamachu S, Derrick R, Howell J (2009) Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 25(12):2877–2885CrossRefPubMed

17.

Smith HS (2013) Considerations in selecting rapid-onset opioids for the management of breakthrough pain. J Pain Res 6:189–200CrossRefPubMedPubMedCentral

18.

Chwieduk CM, McKeage K (2010) Fentanyl sublingual: in breakthrough pain in opioid-tolerant adults with cancer. Drugs 70(17):2281–2288CrossRefPubMed

19.

Überall MA, Müller-Schwefe GH (2011) Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. Curr Med Res Opin 27(7):1385–1394CrossRefPubMed

20.

Lister N, Warrington S, Boyce M, Eriksson C, Tamaoka M, Kilborn J (2011) Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects. J Clin Pharmacol 51(8):1195–1204CrossRefPubMed

21.

Jandhyala R, Fullarton JR, Bennett MI (2013) Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manag 12:1–8

22.

Shimoyama N, Gomyo I, Teramoto O, Kojima K, Higuchi H, Yukitoshi N, Ohta E, Shimoyama M (2015) Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain. Jpn J Clin Oncol 45(2):189–196CrossRefPubMed

23.

Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G (2009) The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13:331–338CrossRefPubMed

Title: The efficacy of oral piroxicam fast-dissolving tablets versus sublingual fentanyl in incident breakthrough pain due to bone metastases: a double-blinded randomized study
Authors: Ayman Abdalmaksoud Yousef
Ashraf Elsayed Alzeftawy
Publication date: 01-06-2019
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 6/2019
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4469-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2019

Caring for the person with cancer and the role of digital technology in supporting carers

Opioid switching and variability in response in pain cancer patients

Social correlates of mental health in gastrointestinal cancer patients and their family caregivers: Exploring the role of loneliness

Comparing fertility preservation resources and policies between NCCN member and non-member institutions

Effect of gastrectomy on blood pressure in early gastric cancer survivors with hypertension

Prognostication in advanced cancer: update and directions for future research

Keynote webinar | Spotlight on antibody–drug conjugates in cancer